The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Pharmaceutical companies aren't often associated with technology prowess, but a select few are trying to change that.
The goal is to hire engineers to help modernize the processes that big pharma uses to discover and develop new drugs.
GSK alone has more than a dozen former employees from the largest tech companies working under its chief data officer Mark Ramsey, who was himself recruited from Samsung. Ramsey is looking to hire "dozens more," from the tech sector according to a GSK spokesperson.
"The pharma industry has been lagging when it comes to tech," said GSK's Ramsey in an interview with CNBC.
Ramsey sees ample opportunities for tech workers to build machine learning tools that analyze health information. One example of that is an ongoing project, depending on a green-light from the U.S. Food and Drug Administration, to use previously-collected clinical trial data as an alternative to a control arm in a study.
That could potentially reduce the cost of clinical trials, and provide a better experience for patients.
Another big area is clinical trial recruitment: Researchers are finding that it's easier, cheaper and reliable enough to find candidates via mobile technologies, versus the alternatives, which involve broad targeting with radio or paper-based ads.
"Digital devices are interesting to us, as they can capture really granular data," he said. "Typically a patient has to go to a clinic and get lab tests, which happens on an infrequent basis."
The big challenge for pharma is to build awareness in the tech community. Ramsey says it's part of his job to educate talented engineers and product managers about "all the cool things that are happening in pharma," and not to be intimidated if they don't have a health background.
Now, he said, about 80 percent of his team has no life sciences experience at all.
J&J's global health of health technology Marc Leibowitz, who previously worked at Google and Dropbox, is also building out a team in San Francisco, New York and other tech hubs.
According to LinkedIn, some of his most senior colleagues include Oliver Hsiang, a former vice president at Lyft who previously worked at Google and LinkedIn, and Jill Applebaum, also formerly of Google.